Skip to main content
. 2020 Nov 29;23(6):983–991. doi: 10.1093/ntr/ntaa241

Table 1.

Baseline Characteristics

Varenicline (n = 50) Control (n = 49) p value
Demographics
Age (mean, SD) 43.0 (12.8) 40.4 (11.5) 0.3
Gender (n, % male) 28 (56%) 14 (29%) 0.006
Race 0.7
 White 40 (80%) 35 (71.4%)
 Black 8 (16%) 10 (20%)
 Multiracial 2 (4%) 3 (6%)
Household income 0.8
 <$25K 16 (32%) 15 (31%)
 $25–$50K 22 (44%) 20 (41%)
 $50–$75K 5 (10%) 6 (12%)
 >$75K 3 (6%) 7 (14%)
Education 0.7
 <HS 2 (4%) 1 (2%)
 HS 13 (26%) 11 (23%)
 Some college 23 (46%) 28 (57%)
 ≥College 12 (24%) 9 (18%)
Rurality 0.2
 Least rural 15 (31%) 8 (16%)
 Moderately rural 23 (47%) 24 (49%)
 Most rural 11 (23%) 17 (35%)
Married or member of unmarried couple 14 (28%) 19 (39%) 0.6
Insured, of any kind 35 (70%) 31 (63%) 0.5
Smoking/Clinical History
Age began smoking 17.3 (4.3) 17.5 (4.2) 0.8
Baseline cigarettes per day (7 day avg) 18.4 (7.2) 15.1 (7.3) 0.03
Cigarette dependence (Heaviness of Smoking Index) 3.4 (1.3) 2.8 (1.5) 0.04
Lives with another smoker 20 (40%) 17 (35%) 0.3
Prior NRT use 34 (68%) 30 (61%) 0.5
Prior varenicline use 5 (10%) 4 (8%) 0.9
Concern about varenicline safety (1–5 range, 5 = most concerned) 2.1 (1.3) 2.1 (1.2) 0.9
History of anxiety 5 (10%) 4 (8%) >0.9
History of depression 7 (14%) 9 (18%) 0.6
Prior E-cigarette use 24 (48%) 22 (45%) 0.8

Bold text refers to statistical significance at p < .05.